Boehringer Ingelheim, Sanofi in Contract Manufacturing Alliance23 January 2015
GERMANY - Boehringer Ingelheim and Sanofi have entered into an alliance to extend Sanofi’s manufacturing capacity network for therapeutic monoclonal antibodies.
Boehringer Ingelheim’s cell culture operations will provide contract manufacturing capacities to support the production of Sanofi’s biologics pipeline.
Under the terms of the agreement, Sanofi will have access to Boehringer Ingelheim’s capabilities to transfer and manufacture therapeutic monoclonal antibodies for global market supply.
Initial product transfers will begin in early 2015.
|ThePigSite News Desk||Read more Boehringer Ingelheim News here|